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Diagnostic delay in individuals with a rare disease is, on average, 4.8 years. Their 
journey to diagnosis, o!en referred to as a diagnostic odyssey, is plagued by countless 
investigations and unsuccessful referrals. How can we ensure that healthcare 
professionals will consider rare diseases when "rst meeting a patient? The answer may 
lie in tackling the issue early on when clinicians begin their journey at medical school. 
The current medical school curriculum approach in the United Kingdom, which 
is largely based on the biomedical model, causes a hindrance in improving rare 
disease diagnosis. Bypassing the cultural, social and psychological considerations 
that a doctor has to address when treating a patient, may contribute to the diagnostic 
odyssey patients have to go through. Further integration of the biopsychosocial 
model into medical teaching can improve the diagnostic journey for patients as well 
as the patient-doctor relationship. The latter could lead to a shorter diagnostic delay 
by increasing compliance and engagement. Additionally, approaching a patient with 
the biopsychosocial model could help their wellbeing and mental health during their 
journey to diagnosis. Integrating rare disease teaching pre-clinically and clinically 
via student selected units (SSU), paediatrics and primary care placements, will 
equip future clinicians with an understanding of rare diseases to ultimately reduced 
diagnostic delay and improve the experience of those living with one.  





Rare diseases - of which there are between 6,000 and 8,000 (1) - 
a#ect fewer than 5 in 10,000 people. (2) They are o!en overlooked 
in medical school education, clinical practice, and research funding. 
I was not aware of rare diseases until more than half-way through 
my medical degree, when I met AL (pseudonym). She had been on 
buprenorphine patches and codeine for osteoarthritis, but they had 
done little to relieve her pain. When I met her, my initial feeling 
was surprise; how could she have osteoarthritis in her late twenties? 
The culprit turned out to be Mucopolysaccharidosis type-I (MPS-
I), a rare hereditary metabolic disorder. Individuals su#ering from 
MPS-I lack the enzyme required for glycosaminoglycan degrada-
tion, leading to its accumulation in tissues, causing skeletal, neuro-
logical and cardiorespiratory problems. (3) AL su#ers from osteope-
nia, osteoporosis, osteoarthritis, kyphosis, carpal tunnel syndrome 
and cardiovascular issues. These have all impaired her mobility and 
le! her as a wheelchair user. Her limited vision and hearing impair-
ment make it di$cult for her to go out alone and have a#ected her 
mental health. As misfortune – or luck – would have it, AL su#ers 
from a severe form of MPS-I; she started showing symptoms early 
on and her diagnosis was not overly delayed. This is imperative. 
Quick diagnosis in rare diseases has been associated with a signi"-
cant reduction in morbidity and mortality. (4) Unfortunately, most 
people a#ected by rare diseases have a di#erent diagnostic journey, 
o!en referred to as a diagnostic odyssey; (5) plagued by an array 
of misdiagnoses and futile investigations. Diagnostic delay is, on 
average, 4.8 years long. (6) Recommendations recently published to 
tackle time-to-diagnosis in rare diseases suggest that primary care 
healthcare professionals should be equipped with diagnostic tools 
and %ow-chart pathways for rare disease identi"cation. This would 
increase the likelihood that correct referrals are carried out. (5) 
Whilst this may accelerate time to diagnosis once a rare disease is 
considered, the clinician "rst has to regard it as a di#erential for the 
appropriate investigations and referrals to take place. How can we 
ensure that healthcare professionals will consider rare diseases when 
diagnosing a patient? The answer may lie in tackling the issue early 
on when clinicians begin their journey at medical school.  
Currently, medical schools in the United Kingdom (UK) adopt 
one of following types of curricula: (1) traditional - a lecture-based 
curriculum where there is a clear pre-clinical and clinical divide; 
(2) problem-based learning where students learn by addressing 
an open-ended problem found in a trigger material; (7) or (3) 
a mixture of both. Regardless of the curriculum type, medical 
schools must comply with the General Medical Council (GMC) 
requirements, the UK public body in charge of the o$cial register 
of doctors. (8) Generally speaking, the content of education across 
medical schools is biomedical in nature, although in varying degrees 
based on the institution and curriculum type used. This type of 
model is strictly focused on biological aspects of illness (9) and 
only super"cially addresses the cultural, social and psychological 
considerations that a doctor has to address when treating a patient. 
The biomedical model reinforces the paternalistic idea that clini-
cal decisions are made based on what the clinician deems to be in 
the patient’s best interest. Within the model, patients’ knowledge 
is considered poor when compared to the clinician, and it takes 
a secondary role when making treatment decisions.  Perhaps it is 
these two aspects of the model, if instilled in medical students early 
on, that contribute to the diagnostic odyssey. This is for two main 
reasons.
Firstly, an individual who presents with a set of symptoms the clini-
cian has never seen before poses a diagnostic challenge.  Clinicians 
may not refer appropriately and investigations which might prove 
ine#ectual may be performed. (3) Throughout this process, the 
patient’s wellbeing and symptom control may su#er as frequent 
investigations take a toll on patients’ mental health. These risks 
are typically not prioritised if a pure biomedical model is ap-
plied in clinical practice. Medical school education has, in the last 
decade, introduced elements of the biopsychosocial model in their 
teaching. This is a holistic and multifactorial approach to clini-
cal practice which includes a strong focus on cultural, social and 
psychological issues. However, it is o!en integrated in the clinical 
years of placement and overshadowed by the practical skills medical 
students need to hone before becoming junior doctors. (7) Time 
and time again, medical students are reminded that “when you hear 
hooves, think horses not zebras.” An aphorism coined in the late 
1940s, (10) it serves as a reminder to medical students that common 
conditions are, by default, common. When a patient presents with 
certain symptoms or signs, you should always consider the most 
prevalent causes "rst before considering rarer di#erentials. Although 
important when teaching medical students how to approach a 
clinical consultation, by focusing too much on what is common, 
and o!en not considering what is rare, are we doing patients a 
disservice? I believe the diagnostic odyssey experience in patients 
with rare diseases would be improved if medical school programmes 
integrated the ‘biopsychosocial’ model earlier on by incorporating 
more behavioural and social sciences alongside pathophysiology and 
pharmacology. This is because by equipping students with “so! 
skills” developed through this model, future clinicians will be able 
to more promptly respond to the emotional needs of a patient who 
might still not have a diagnosis. Whilst this may not shorten their 
journey to diagnosis, it will hopefully improve their wellbeing and 
mental health whilst waiting for one. 
A major challenge with achieving this is that the National Health 
Service (NHS) is a taxpayer-funded system that faces constant 
pressures due to under-sta$ng. Delivering holistic care in a system 
like this is not easy; most clinicians probably do recognise the 
emotional needs of their patients but responding adequately in a 
system dictated by short appointment times and ever-increasing 
workload is challenging. Crucially, it is because of these pressures 
that further integration of the ‘biopsychosocial’ model would better 
enable clinicians to respond to the needs of patients, especially those 
with rare disease or complex co-morbidities. Training individuals 
early on to weigh biomedical, social and psychological factors that 
a#ect a patient equally in every consultation means that they will 
have practised identifying which factors are most important to the 
patient and should be dealt with "rst. This is key, especially since 
appointments can be as short as eight minutes in duration. (11) 
I wish I had witnessed this "rst-hand in the case of VL, a 7-year old 





by seizures that increase in frequency and severity due to brain 
in%ammation. This then leads to hemiparesis which with time, 
continues to weaken and can lead to complete loss of limb func-
tion. (12) Conducting the consultation with VL’s parents using a 
‘biopsychosocial’ approach might have helped the clinician identify 
VL’s parents’ main concerns early in the conversation. It might 
have prompted the clinician to act on VL’s parents’ worry that as 
he grows up and becomes more active, his risk of injury, should he 
have a seizure or experience limb weakness, may increase. Indeed, 
a few weeks later he was injured as he was playing in a public 
playground, exactly as his parents had feared. This risk, which 
could have been initially mitigated with a referral for Occupational 
Therapy assessment, was not prioritised when using a biomedical 
approach as the social issues were not discussed during the con-
sultation. Ultimately, this could have spared VL and his family the 
physical and psychological pain and engendered greater trust in the 
healthcare system. 
While a biopsychosocial model might not always shorten time to 
diagnosis directly, it can indirectly shorten a patient’s diagnostic 
odyssey by improving the relationship between the doctor and the 
patient. A 2019 observational study reported that consultations with 
con%icting points of views between the patient and the practi-
tioner not only led to mistrust but to unhelpful patient behaviour 
(non-attendance). (13) This can lead to both patient harm and 
extended diagnostic delay; especially crucial in the context of rare 
diseases where symptoms and signs are o!en harder to diagnose 
and diagnostic delay is already unacceptably long. (6) Addition-
ally, engagement between the clinician and the patient – which is 
a key component of the ‘biopsychosocial’ model – has been shown 
to improve diagnostic odyssey experience in rare diseases, (14) 
reinforcing the argument for its integration in the medical school 
curriculum earlier on. 
Secondly, the inherent assumption perpetuated by the biomedical 
model that patients and family members’ knowledge is poor, has 
to be removed early on. Over the months and years that patients 
live with a condition, they become experts on how to manage the 
symptoms they experience. Their expertise can aid diagnosis and 
reduce diagnostic delay but only if clinicians listen to their patients’ 
concerns and expectations and accept that they may know less than 
their patient.  
The biomedical model perpetuates this bias because it trains medi-
cal students to associate success with being able to identify and 
treat symptoms and signs of a disease, and not the individual as a 
whole. Treatment o!en focuses on something tangible that can be 
measured, like pharmacotherapy. This leads to an overshadowing 
of social and psychological aspects the patient might be concerned 
with. Better outcomes could be achieved if the patient’s issues are 
being dealt with holistically and not only from a biomedical point of 
view. In the case of a rare disease like MPS-I, patients o!en strug-
gle to use "ne motor skills because of the pain they experience. If 
a piano teacher, still undiagnosed, was presenting to her general 
practitioner (GP) with arthritic-type symptoms, the clinician might 
focus on following a biomedical model to diagnosis and prescribe 
pharmacotherapy for the pain and refer for investigations. If you 
applied the biopsychosocial model you would also consider the 
threat to her job security. If she couldn’t teach piano, how would 
she pay for her house and her bills? What e#ect would that have 
on her pain, her wellbeing and mental health? Could it indirectly 
negatively impact any other co-morbidities she may already have? 
Discussing this could lead to a referral to a link worker for social 
prescribing (15) which would then put the patient in contact with 
volunteer organisations and charities that can help with social is-
sues. Applying the biopsychosocial model would not only focus on 
identifying the cause and treating the problem (the pain), which is 
an aspect of both the biomedical and biopsychosocial model, but on 
identifying interim solutions while the diagnosis is being pursued. 
This will make the investigations to diagnosis more manageable for 
the patient. 
Adoption of a biopsychosocial approach has been extensively 
researched in chronic illness, autoimmune diseases, functional 
diseases and in psychiatry. (16-18) Its utilisation has been shown to 
improve patient trust and satisfaction, medication adherence once 
diagnosed, promote positive behavioural change and a better qual-
ity of life. (16-19) Research has also shown that the adoption of the 
biopsychosocial model can reduce the amount of diagnostic tests 
and referrals as the relationship fostered between the doctor and 
the patient reassures patients that a common ground can be found 
between both parties. (20) Rare diseases like MPS-I or Rasmus-
sen syndrome are o!en chronic or progressive, which supports the 
argument for approaching patients who might have a rare disease 
using the biopsychosocial model. 
Not only does the model lead to better health outcomes physically, 
but it can also address the non-biomedical aspects of living and the 
psychological factors that may a#ect patients’ wellbeing. These, 
if given consideration, can be targeted with an appropriate inter-
vention whilst developing an individual diagnostic and treatment 
strategy more speci"c to the array of symptoms and social issues 
the patient may face during diagnosis. (6) Additionally, patients 
with rare diseases o!en experience issues when communicating 
with medical professionals who do not believe their symptoms (21) 
or who are themselves frustrated with a lack of diagnosis. This has 
negative repercussions on both the patient and the length of time to 
diagnosis. (21) Theoretical knowledge of a disease is not a replace-
ment for years of experience. Involving the patient in decision-
making and in addressing what is important for the patient may 
not only shorten the diagnostic odyssey but may make the journey 
to diagnosis better and improve the rapport between patients and 
healthcare professionals. 
Not only should the biopsychosocial model be integrated more 
fully in current medical curricula across the UK but changes should 
be made to the content of the curriculum itself. Until recently, 
there was no standardised curriculum across UK medical schools, 
the topics covered were partly dependent on what was deemed 
clinically useful, and partly on the healthcare opportunities available 






Assessment (MLA) curriculum (23) for the graduating year 
of 2023-24 this will change. The MLA curriculum outlines a list of 
conditions that medical students are required to understand by the 
time they graduate; this knowledge will then be tested in a national 
exam medical students will be required to sit in order to gradu-
ate. Encouragingly, a few rare diseases are mentioned in the MLA 
curriculum; muscular dystrophies, myeloproliferative disorders 
and polymyalgia rheumatica. However, two are umbrella terms for 
groups of conditions – muscular dystrophies, myeloproliferative 
disorders – and the curriculum does not specify how much time 
should be spent on each topic and in what format that should be 
taught. Understandably, as di#erent curricula types employ dif-
ferent teaching methods, this gives medical schools the freedom to 
integrate the MLA curriculum requirements within their current 
curriculum without having to re-design a completely new course. 
However, as no timeframe is speci"ed, this caveat might result in 
some universities deeming one lecture enough to ful"l the require-
ment while another could allocate a week of theoretical and clinical 
work to rare diseases. This would lead to a discrepancy in knowl-
edge between graduating students from di#erent institutions. 
It is also important to consider that collectively, rare diseases a#ect 
1 in 17 patients. (2) Tomorrow’s doctors must be able to recog-
nise a patient who could be a#ected by a rare disease, even if they 
cannot diagnose the rare disease at "rst presentation. Being able 
to consider a rare disease can only occur if students have engaged 
with patients who have experienced the diagnostic odyssey them-
selves - the signs and symptoms may be di#erent in the patient 
they encounter as a clinician compared to the patient they met at 
medical school, but similar diagnostic patterns will be present. (24) 
Following GMC recommendation, this is already integrated to a 
varying extent in UK medical schools by having expert patients for 
conditions that medical students will o!en see as clinicians. So why 
not have some rare disease patients as expert patients? (25) A!er all, 
who better than someone who has lived through the diagnostic od-
yssey to explain to medical students their disease and experiences? 
It is not only bene"cial for the patients that medical students will 
encounter in future, but to the students too, as engagement with 
expert patients has been reported to increase con"dence in clinical 
decision making. (26)  Self-con"dence has been shown to be an 
important resource for e#ective clinical decisions that improve 
patient diagnosis and management. (27)
With over 180 rare disease patient organisations present in the 
UK, integrating rare diseases into medical school teaching via 
expert patients is a feasible short-term task. (28) It will provide 
future clinicians with an insight into rare diseases, the struggles of 
the diagnostic odyssey and an awareness into what living with a 
rare disease within the NHS is really like. Expert patient integra-
tion into the curriculum could then be followed by long-term 
curriculum changes, for example via student selected units and 
elective opportunities for students who wish to learn more about 
rare diseases. Additionally, medical schools could also integrate rare 
disease teaching in parts of the syllabus where they are commonly 
encountered, such as paediatrics and primary care. Future clinicians 
who choose to train in these specialties would therefore already 
have an understanding of rare diseases and how they may present 
before they qualify. All of these changes would, in turn, equip fu-
ture clinicians with an awareness that is currently lacking in clinical 
practice and help rare disease patients by feeling heard, accounted 
for and considered. Ultimately, the patient’s healthcare experience 
would be improved. Further integrating the biopsychosocial model 
and rare diseases teaching in medical education would enable 
current medical students to be better clinicians and to serve the 
purpose they set out to ful"l when they enrolled in medical school: 
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